• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺眼病合并重症肌无力的临床研究

Clinical study of thyroid eye disease combined with myasthenia gravis.

作者信息

Wu Yi, Li Yanxi, He Weimin

机构信息

Department of Ophthalmology, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan, China.

出版信息

Jpn J Ophthalmol. 2025 May 5. doi: 10.1007/s10384-025-01208-0.

DOI:10.1007/s10384-025-01208-0
PMID:40323520
Abstract

PURPOSE

To investigate the clinical features and prognostic factors of patients with thyroid eye disease (TED) combined with myasthenia gravis (MG) at a tertiary comprehensive hospital in China during a 10-year period.

STUDY DESIGN

retrospective study.

METHODS

A case series of patients diagnosed with TED combined with MG was conducted at a tertiary general hospital over 10 years. Medical records of general conditions, clinical presentation, imaging and laboratory tests, treatment modalities, and prognostic outcomes were reviewed.

RESULTS

Twenty-three patients with TED combined with MG were found throughout the study period. The mean age was 42.57 ± 14.89 years with 10 men and 13 women. Ocular motility disorders (82.61%), diplopia (73.91%), and ptosis (73.91%) were the primary clinical manifestations, and ocular motility disorders with limited movement in all directions were common (17 eyes) (50.00%). Active (69.57%) and moderate-to-severe (82.61%) TED was common, and hyperthyroidism was the most common complication of thyroid disease (57.17%). Ocular MG was the predominant subtype of MG (86.96%). Chest CT or pathologic examination identified thymic hyperplasia in 4 patients (17.39%) and thymoma in 1 patient (4.35%). A statistically significant association was observed between smoking and an unfavorable prognosis of TED combined with MG (P<0.05).

CONCLUSIONS

MG should be taken into account in patients with TED who exhibit the following: unilateral or bilateral ptosis, ptosis in one eye and upper eyelid retraction in the other, obvious eye movement disorders without or with mild involvement of the extraocular muscles on imaging, and symptoms of morning and evening fluctuations. Ophthalmologists should refer these patients to the Department of Neurology to avoid misdiagnosis or underdiagnosis. The co-occurrence of TED and MG is rare clinically, mostly affecting young and middle-aged women, with ocular MG and hyperthyroidism as the main clinical subtype, and thymic hyperplasia or thymoma in a small percentage. Smoking is an independent risk factor for poor prognosis of TED combined with MG.

摘要

目的

调查中国一家三级综合医院10年间甲状腺眼病(TED)合并重症肌无力(MG)患者的临床特征及预后因素。

研究设计

回顾性研究。

方法

在一家三级综合医院对10年间诊断为TED合并MG的患者进行病例系列研究。回顾患者的一般情况、临床表现、影像学及实验室检查、治疗方式及预后结果等病历资料。

结果

研究期间共发现23例TED合并MG患者。平均年龄为42.57±14.89岁,男性10例,女性13例。主要临床表现为眼球运动障碍(82.61%)、复视(73.91%)和上睑下垂(73.91%),各方向运动受限的眼球运动障碍较为常见(17只眼)(50.00%)。活动期(69.57%)和中重度(82.61%)TED较为常见,甲状腺疾病最常见的并发症是甲状腺功能亢进(57.17%)。眼肌型MG是MG的主要亚型(86.96%)。胸部CT或病理检查发现4例(17.39%)胸腺增生,1例(4.35%)胸腺瘤。吸烟与TED合并MG的不良预后之间存在统计学显著关联(P<0.05)。

结论

对于出现以下情况的TED患者应考虑合并MG:单侧或双侧上睑下垂、一眼上睑下垂另一眼上睑退缩、影像学显示明显眼球运动障碍且眼外肌无或轻度受累、有晨轻暮重症状。眼科医生应将这些患者转诊至神经内科,以避免误诊或漏诊。TED与MG临床共发少见,主要影响中青年女性,以眼肌型MG和甲状腺功能亢进为主要临床亚型,少数伴有胸腺增生或胸腺瘤。吸烟是TED合并MG预后不良的独立危险因素。

相似文献

1
Clinical study of thyroid eye disease combined with myasthenia gravis.甲状腺眼病合并重症肌无力的临床研究
Jpn J Ophthalmol. 2025 May 5. doi: 10.1007/s10384-025-01208-0.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study.在全身型重症肌无力患者中从静脉注射补体成分5抑制剂转换为皮下注射zilucoplan:一项IIIb期开放标签研究。
Ther Adv Neurol Disord. 2025 Jul 5;18:17562864251347283. doi: 10.1177/17562864251347283. eCollection 2025.
4
Comparison of outcomes and postoperative immunotherapy between patients with non-thymomatous and thymomatous myasthenia gravis following thymectomy.胸腺切除术后非胸腺瘤型与胸腺瘤型重症肌无力患者的预后及术后免疫治疗比较。
Ther Adv Neurol Disord. 2025 Jun 20;18:17562864251343573. doi: 10.1177/17562864251343573. eCollection 2025.
5
Accuracy of Repetitive Ocular Vestibular-Evoked Myogenic Potentials to Diagnose Myasthenia Gravis in Patients With Ptosis or Diplopia.反复性眼前庭肌源性电位诊断伴眼睑下垂或复视的重症肌无力患者的准确性。
Neurology. 2024 May;102(10):e209395. doi: 10.1212/WNL.0000000000209395. Epub 2024 Apr 26.
6
Interventions for eye movement disorders due to acquired brain injury.针对后天性脑损伤所致眼球运动障碍的干预措施。
Cochrane Database Syst Rev. 2018 Mar 5;3(3):CD011290. doi: 10.1002/14651858.CD011290.pub2.
7
Thyroid surgery for Graves' disease and Graves' ophthalmopathy.用于治疗格雷夫斯病和格雷夫斯眼病的甲状腺手术。
Cochrane Database Syst Rev. 2015 Nov 25;2015(11):CD010576. doi: 10.1002/14651858.CD010576.pub2.
8
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.在重症肌无力(PROMISE-MG)中,硫唑嘌呤和霉酚酸酯的疗效比较:一项前瞻性队列研究。
Lancet Neurol. 2024 Mar;23(3):267-276. doi: 10.1016/S1474-4422(24)00028-0.
9
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.在重症肌无力(MG-001)中自体 RNA 嵌合抗原受体 T 细胞治疗的安全性和临床活性:前瞻性、多中心、开放标签、非随机 1b/2a 期研究。
Lancet Neurol. 2023 Jul;22(7):578-590. doi: 10.1016/S1474-4422(23)00194-1.
10
Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of two different treatment approaches.评估ravulizumab或efgartigimod对重症肌无力症状的控制:两种不同治疗方法的患者体验评估
Curr Med Res Opin. 2025 May;41(5):817-827. doi: 10.1080/03007995.2025.2497906. Epub 2025 May 24.

本文引用的文献

1
Ophthalmologic clinical features of ocular myasthenia gravis.眼肌型重症肌无力的眼科临床特征。
Medicine (Baltimore). 2023 Jan 13;102(2):e31972. doi: 10.1097/MD.0000000000031972.
2
Current Treatment of Myasthenia Gravis.重症肌无力的当前治疗方法
J Clin Med. 2022 Mar 14;11(6):1597. doi: 10.3390/jcm11061597.
3
Blepharoptosis in thyroid eye disease: etiopathogenesis, clinical features and correlation with thyroid eye disease.甲状腺相关眼病中的上睑下垂:发病机制、临床特征及与甲状腺眼病的相关性。
Int Ophthalmol. 2022 Jan;42(1):13-18. doi: 10.1007/s10792-021-01992-x. Epub 2021 Aug 4.
4
Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study.中国重症肌无力的发病率、死亡率及经济负担:一项基于全国人群的研究。
Lancet Reg Health West Pac. 2020 Nov 27;5:100063. doi: 10.1016/j.lanwpc.2020.100063. eCollection 2020 Dec.
5
Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy.格雷夫斯眼病的流行病学、自然史、危险因素和预防。
Front Endocrinol (Lausanne). 2020 Nov 30;11:615993. doi: 10.3389/fendo.2020.615993. eCollection 2020.
6
Myasthenia Gravis and its Association With Thyroid Diseases.重症肌无力及其与甲状腺疾病的关联。
Cureus. 2020 Sep 4;12(9):e10248. doi: 10.7759/cureus.10248.
7
Peribulbar injection of glucocorticoids for thyroid-associated ophthalmopathy and factors affecting therapeutic effectiveness: A retrospective cohort study of 386 cases.球周注射糖皮质激素治疗甲状腺相关性眼病及影响治疗效果的因素:一项对386例患者的回顾性队列研究
Exp Ther Med. 2020 Sep;20(3):2031-2038. doi: 10.3892/etm.2020.8896. Epub 2020 Jun 17.
8
Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody.影响乙酰胆碱受体抗体阳性的眼肌型重症肌无力患者泛化的因素。
Am J Ophthalmol. 2020 Jan;209:10-17. doi: 10.1016/j.ajo.2019.09.019. Epub 2019 Sep 25.
9
Neuroradiological and clinical features in ophthalmoplegia.眼肌麻痹的神经放射学和临床特征。
Neuroradiology. 2019 Apr;61(4):365-387. doi: 10.1007/s00234-019-02183-3. Epub 2019 Feb 12.
10
Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis.胸腺切除术治疗非胸腺瘤型眼肌型重症肌无力患者的疗效:系统评价和荟萃分析。
Neurol Sci. 2017 Oct;38(10):1753-1760. doi: 10.1007/s10072-017-3058-7. Epub 2017 Jul 13.